Company Overview - Shanghai Youningwei Biotechnology Co., Ltd. introduced its basic situation and 2024 operational performance during the investor relations activity [2]. Impact of Tariff Policies - The impact of increased tariffs on exports is minimal due to the low export ratio; however, it affects imports from the U.S. and promotes the development of the company's own brand [2]. Business Strategy for 2024 - The company will focus on a one-stop platform strategy and antibody strategy, increasing investment in R&D, promoting its own brand, and enhancing operational efficiency through information technology [2]. R&D Investment - In 2024, R&D investment reached CNY 62.77 million, a year-on-year increase of 7.10%, with R&D expenditure accounting for 5.62% of revenue [3]. Product Development - The company has significantly increased its product offerings, with over 2,900 products developed at the Nanjing Protein R&D Center and a nearly 30% year-on-year growth in revenue from its own brand in 2024 [3]. Share Buyback Program - In 2024, the company initiated a share buyback plan, utilizing CNY 25,987,076 to repurchase shares for employee stock ownership plans, aiming to enhance investor confidence and promote sustainable development [3]. Future Market Strategy - The company plans to enrich its product system and enhance both third-party and self-owned brand offerings, leveraging 20 years of experience in life sciences to provide comprehensive solutions to meet diverse customer needs [3].
优宁维(301166) - 301166优宁维投资者关系管理信息20250425